Skip to main content

Prothena Corporation plc

corporate_fare Company Profile

Prothena Corporation plc

PRTA·NASDAQ·Life Sciences·CIK 0001559053

Prothena Corporation plc is a late-stage clinical biotechnology company specializing in protein dysregulation to address neurodegenerative and rare peripheral amyloid diseases. The company leverages its scientific expertise to develop a pipeline of therapeutic candidates for various indications and targets. Prothena's pipeline includes both wholly-owned and partnered programs aimed at treating diseases such as Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative conditions. The company also utilizes its proprietary CYTOPE® technology to target intracellular disease pathways in the brain and periphery. Prothena was formed on September 26, 2012, in Ireland, and re-registered as an Irish public limited company on October 25, 2012. Its ordinary shares began trading on The Nasdaq Global Market under the symbol "PRTA" on December 21, 2012, and now trade on The Nasdaq Global Select Market. The company's strategy is to discover and develop novel therapies for diseases caused by protein dysregulation, where misfolded proteins aggregate to form amyloid, damaging vital organs. For example, Parkinson's disease involves neuronal dysfunction and loss due to the spread of toxic aggregated alpha-synuclein protein.

Prothena Corporation plc (NASDAQ:PRTA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 15 items for PRTA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 15 most recent items scored 7 or higher, the top rating is 9/10, with 7 rated 8 or above. Recent SEC coverage for PRTA spans 8-K, 10-Q, 144, DEF 14A.

Recent high-impact activity:

  • Prothena Q3 Loss Widens to 32 Cents a Share, Revenue Collapses 74%
  • Prothena Q3 2026: Net Loss Narrows to $16.5M, Cash $272.2M, Burn Guidance Held
  • BMS Terminates PRX019 License; Prothena Loses Up to $617.5M in Milestones
  • Prothena Q2 2026: Net Loss Narrows to $18.6M as Restructuring Winds Down; Cash at $288M
  • Prothena Posts Q2 Results, Highlights $3B in Potential Milestones from Partnered Pipeline

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$9.68M
Net Income
-$244.09M
Diluted EPS
-$4.53
Op. Cash Flow
-$163.58M
Operating Income
-$214.64M
Cash & Equivalents
$307.53M
Debt / Equity
0.00×
Net Margin
-25.21×
Shares Outstanding
53.83M sh
Source: 10-K · filed 2026-02-27 · accession 0001559053-26-000008

Short Interest & Short Volume

15.69 days to cover

FINRA reported short interest of 7,911,160 shares in PRTA as of the October 30, 2026 settlement, a 0.4% decrease from the prior period — about 15.7 days to cover at its recent average daily volume. On November 20, 2026, 44.9% of PRTA volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)7,911,160 shares as of October 30, 2026
Change vs prior period▼ 0.4%
Days to cover15.69 at avg daily volume of 504,196
Daily short volume (FINRA facilities)44.9% of 252,812 shares on November 20, 2026
5-day average short volume56.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with P →
$8.2 -0.24% today
52-week range · as of 2026-11-05 $7.73 – $11.8
Market cap
$422.1M
Volume
862K (1.7× avg)
3-mo avg 495K
Live data · 2026-11-22 06:08 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed PRTA - Latest Insights

PRTA
Nov 05, 2026, 5:55 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $7.89
Real-time Price: $8.20 info
Change: +$0.310 (+4%) info
Market Cap: $422.095M info
PRTA
Nov 05, 2026, 4:07 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.89
Real-time Price: $8.20 info
Change: +$0.310 (+4%) info
Market Cap: $422.095M info
PRTA
Oct 29, 2026, 4:03 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.88
Real-time Price: $8.20 info
Change: -$0.680 (-8%) info
Market Cap: $422.095M info
PRTA
Aug 06, 2026, 4:20 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $8.58
Real-time Price: $8.20 info
Change: -$0.380 (-4%) info
Market Cap: $422.095M info
PRTA
Aug 06, 2026, 4:05 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $8.58
Real-time Price: $8.20 info
Change: -$0.380 (-4%) info
Market Cap: $422.095M info
PRTA
Jun 09, 2026, 8:00 AM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $8.71
Real-time Price: $8.20 info
Change: -$0.510 (-6%) info
Market Cap: $422.095M info
PRTA
May 07, 2026, 4:32 PM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $10.53
Real-time Price: $8.20 info
Change: -$2.33 (-22%) info
Market Cap: $422.095M info
PRTA
May 07, 2026, 4:20 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $10.53
Real-time Price: $8.20 info
Change: -$2.33 (-22%) info
Market Cap: $422.095M info
PRTA
May 07, 2026, 4:14 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $10.53
Real-time Price: $8.20 info
Change: -$2.33 (-22%) info
Market Cap: $422.095M info
PRTA
Apr 27, 2026, 4:07 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $11.34
Real-time Price: $8.20 info
Change: -$3.14 (-28%) info
Market Cap: $422.095M info
PRTA
Mar 27, 2026, 4:03 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $9.26
Real-time Price: $8.20 info
Change: -$1.06 (-11%) info
Market Cap: $422.095M info
PRTA
Feb 27, 2026, 4:45 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $9.01
Real-time Price: $8.20 info
Change: -$0.810 (-9%) info
Market Cap: $422.095M info
PRTA
Feb 27, 2026, 4:15 PM EST
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $9.81
Real-time Price: $8.20 info
Change: -$1.61 (-16%) info
Market Cap: $422.095M info
PRTA
Feb 27, 2026, 4:04 PM EST
Filing Type: 10-K
Importance Score:
7
Price at Filing: $9.15
Real-time Price: $8.20 info
Change: -$0.9499 (-10%) info
Market Cap: $422.095M info
PRTA
Feb 19, 2026, 4:07 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $9.03
Real-time Price: $8.20 info
Change: -$0.830 (-9%) info
Market Cap: $422.095M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets